Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
8 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 40(1); March 2008
Prev issue Next issue
Original Articles
The Increasing Frequency of Cervical Cancer in Korean Women under 35
Chan Hee Han, Hyun Jung Cho, Sung Jong Lee, Jeong Hoon Bae, Seog Nyen Bae, Sung Eun Namkoong, Jong Sup Park
Cancer Res Treat. 2008;40(1):1-5.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.1
AbstractAbstract PDFPubReaderePub
Purpose

The goal of this study was to determine the clinical and epidemiological trends of cervical cancer in young Korean women. Social behavior including sexual habits has changed in Korean women, with sexual activity commencing at a younger age. These changes are likely to influence certain risk factors of cervical cancer, resulting in changing trends in the occurrence of the disease.

Materials and Methods

The incidence of cervical cancer in women less than 35 years-old between January 1990 and December 2006 was analyzed, and available medical records from January 1996 to December 2006 were reviewed. The clinical, pathological and epidemiologic characteristics and changing trends among these young patients were analyzed.

Results

Over the last two decades, the incidence of young (< 35 years) cervical cancer patients increased, more patients had an aggressive form of the disease, and there was a higher rate of women with more advanced education. Human papillomavirus (HPV) infection was detected in 94.0% of the women (63/67) tested. HPV 16 (82.5%) and HPV 18 (12.7%) were the two most common viral infections detected throughout the study period.

Conclusions

The changing trends and risk factors identified suggest a need for more active education of young women about cervical cancer prevention strategies. In addition, young women are strongly recommended to undergo a regular screening test and HPV vaccination.

Citations

Citations to this article as recorded by  
  • Prevalence and Treatment of Vulvar Cancer From 2014−2018: A Nationwide Population-Based Study in Korea
    Yung-Taek Ouh, Dongwoo Kang, Hoseob Kim, Jae Kwan Lee, Jin Hwa Hong
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Successful Treatment of Synchronous Double Lung Primary Malignancies and Colon Cancer
    Hosam A Alghanmi
    Cureus.2022;[Epub]     CrossRef
  • WITHDRAWN: Polymerase chain reaction technique for molecular detection of HPV16 infections among women with cervical cancer in Dhi-Qar Province
    Abduladheem Turki Jalil, Ali Hussein Demin Al-Khafaji, Aleksandr Karevskiy, Saja Hussain Dilfy, Zaman K. Hanan
    Materials Today: Proceedings.2021;[Epub]     CrossRef
  • Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview
    Min-A Kim, Gwan Hee Han, Jae-Hoon Kim, Kyung Seo
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Management for locally advanced cervical cancer: new trends and controversial issues
    Oyeon Cho, Mison Chun
    Radiation Oncology Journal.2018; 36(4): 254.     CrossRef
  • Trends and Age-Period-Cohort Effects on the Incidence and Mortality Rate of Cervical Cancer in Korea
    Eun-Kyeong Moon, Chang-Mo Oh, Young-Joo Won, Jong-Keun Lee, Kyu-Won Jung, Hyunsoon Cho, Jae Kwan Jun, Myong Cheol Lim, Moran Ki
    Cancer Research and Treatment.2017; 49(2): 526.     CrossRef
  • Factors associated with participation in cervical cancer screening among young Koreans: a nationwide cross-sectional study
    Ha Kyun Chang, Jun-Pyo Myong, Seung Won Byun, Sung-Jong Lee, Yong Seok Lee, Hae-Nam Lee, Keun Ho Lee, Dong Choon Park, Chan Joo Kim, Soo Young Hur, Jong Sup Park, Tae Chul Park
    BMJ Open.2017; 7(4): e013868.     CrossRef
  • Molecular Detection and Typing of Human Papillomaviruses in Paraffin-Embedded Cervical Cancer and Pre-Cancer Tissue Specimens
    Pezhman Mahmoodi, Hossein Motamedi, Masoud Reza Seyfi Abad Shapouri, Mahjabin Bahrami Shehni, Mohammad Kargar
    Iranian Journal of Cancer Prevention.2016;[Epub]     CrossRef
  • Cervical cancer in north-eastern Libya: 2000–2008
    F. Ben Khaial, Z. Bodalal, A. Elramli, F. Elkhwsky, A. Eltaguri, R. Bendardaf
    Journal of Obstetrics and Gynaecology.2014; 34(6): 523.     CrossRef
  • Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009
    Young Hwa Lee, Kui Son Choi, Hoo-Yeon Lee, Jae Kwan Jun
    Journal of Gynecologic Oncology.2012; 23(1): 16.     CrossRef
  • Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study
    J.-H. Nam, J.-Y. Park, D.-Y. Kim, J.-H. Kim, Y.-M. Kim, Y.-T. Kim
    Annals of Oncology.2012; 23(4): 903.     CrossRef
  • The safety of conization in the management of adenocarcinomain situof the uterine cervix
    Mi-La Kim, Ho-Suap Hahn, Kyung-Taek Lim, Ki-Heon Lee, Hy-Sook Kim, Sung-Ran Hong, Tae-Jin Kim
    Journal of Gynecologic Oncology.2011; 22(1): 25.     CrossRef
  • Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
    Seung Cheol Kim, Yong Sang Song, Young-Tae Kim, Young Tak Kim, Ki-Sung Ryu, Bhavyashree Gunapalaiah, Dan Bi, Hans L Bock, Jong-Sup Park
    Journal of Gynecologic Oncology.2011; 22(2): 67.     CrossRef
  • Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer
    Hyun Hoon Chung, Jae Weon Kim, Kyung Hee Han, Jae Seon Eo, Keon Wook Kang, Noh-Hyun Park, Yong-Sang Song, June-Key Chung, Soon-Beom Kang
    Gynecologic Oncology.2011; 120(2): 270.     CrossRef
  • 12,646 View
  • 130 Download
  • 14 Crossref
Close layer
Endometrial Stromal Sarcomas: A Retrospective Analysis of 28 Patients, Single Center Experience for 20 Years
Eun Ji Nam, Jae Wook Kim, Dae Woo Lee, Si Young Jang, Jong Wook Hong, Young Tae Kim, Jae Hoon Kim, Sunghoon Kim, Sang Wun Kim
Cancer Res Treat. 2008;40(1):6-10.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.6
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESSs) in relation to their clinical and pathogenic features, and to determine the optimal treatment strategy.

Materials and Methods

A retrospective analysis was performed involving 28 patients with histologic-proven ESSs treated at our institution between 1987 and 2006.

Results

The median follow-up was 54.7±63.1 months and the 5-year survival rate was 82.0%. Twenty-two (81.5%) and 5 patients (18.5%) had low- and high-grade disease, respectively. Univariate analysis revealed that the histologic grades, based on mitotic count, were associated with longer survival (p=0.004). However, among those patients with low-grade tumors, 5/20 patients (25%) had a recurrence and 2/21 patients (9.5%) had distant metastasis during the follow-up period. With the exception of 2 patients, 26 patients with ESSs underwent hysterectomy as primary treatment. Adjuvant treatment after surgery was administered to 14/26 patients (53.8%). Hormone therapy with progesterone, chemotherapy, and/or radiotherapy did not influence overall survival. However, the postoperative adjuvant therapy group, regardless of the treatment modality, was associated with relatively increased overall survival when compared to the surgery only group (p=0.054).

Conclusions

The preoperative differential diagnosis of ESSs from other benign gynecologic diseases is often difficult. We recommend adjuvant therapy be administered after hysterectomy in patients with ESS to prevent recurrence or distant metastasis.

Citations

Citations to this article as recorded by  
  • Laparoscopic surgery on broken points for uterine sarcoma in the early stage decrease prognosis
    Hong Liu, Yi Zhu, Guo-Nan Zhang, Chang Wang, Chao Li, Yu Shi
    Scientific Reports.2016;[Epub]     CrossRef
  • Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study
    Hiroyuki Yamazaki, Yukiharu Todo, Kenrokuro Mitsube, Hitoshi Hareyama, Chisa Shimada, Hidenori Kato, Katsushige Yamashiro
    Journal of Gynecologic Oncology.2015; 26(3): 214.     CrossRef
  • Management of uterine adenosarcomas with and without sarcomatous overgrowth
    Edward J. Tanner, Thomas Toussaint, Mario M. Leitao, Martee L. Hensley, Robert A. Soslow, Ginger J. Gardner, Elizabeth L. Jewell
    Gynecologic Oncology.2013; 129(1): 140.     CrossRef
  • Uterine Sarcomas: Then and Now
    Shaan H. Shah, Jyothi P. Jagannathan, Katherine Krajewski, Kevin N. O???Regan, Suzanne George, Nikhil H. Ramaiya
    American Journal of Roentgenology.2012; 199(1): 213.     CrossRef
  • Role of radiotherapy treatment of uterine sarcoma
    Sagus Sampath, David K. Gaffney
    Best Practice & Research Clinical Obstetrics & Gynaecology.2011; 25(6): 761.     CrossRef
  • Surgical treatment of uterine sarcoma
    Joo-Hyun Nam
    Best Practice & Research Clinical Obstetrics & Gynaecology.2011; 25(6): 751.     CrossRef
  • The Impact of Tumor Morcellation During Surgery on the Outcomes of Patients with Apparently Early Low-Grade Endometrial Stromal Sarcoma of the Uterus
    Jeong-Yeol Park, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
    Annals of Surgical Oncology.2011; 18(12): 3453.     CrossRef
  • 10,577 View
  • 139 Download
  • 7 Crossref
Close layer
A Phase II Study of Leucovorin, 5-FU and Docetaxel Combination Chemotherapy in Patients with Inoperable or Postoperative Relapsed Gastric Cancer
Kwang-Sun Lee, Ha-Yeon Lee, Eun-Kyung Park, Joung-Soon Jang, Sang-Jae Lee
Cancer Res Treat. 2008;40(1):11-15.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.11
AbstractAbstract PDFPubReaderePub
Purpose

To estimate the effect and toxicity of bimonthly low-dose leucovorin (LV) and fluorouracil (5-FU) bolus plus continuous infusion(LV5FU2) with docetaxel combination chemotheraphy in patients with inoperable or postoperative relapsed gastric cancer.

Materials and Methods

Total 27 patients are enrolled in this study. LV 20 mg/m2 (bolus), 5FU 400 mg/m2 (bolus), 5-FU 600 mg/m2 (24-hour continuous infusion) on day 1, 2, 15, and 16, docetaxel 60 mg/m2 (1-hour infusion) on day 15 every 4 weeks.

Results

Total of 141 cycles were administered and response rate were 36.8% with 2 complete response (10.5%) and 5 partial response (26.3%) in 19 evaluable patients. The median response duration is 8.1 months (95% CI, 4.0~12.1). The median progression-free survival time is 6.7 months (95% CI, 5.0~8.5) and the median overall survival time is 11.9 months (95% CI, 4.8~19.1). The grade 3-4 toxcity of neutropenia (24.8%) and anemia (11.3%), neutropenic fever (2.8%) is observed. The grade 1 toxcity of injection site reaction is observed all patients and the grade 1-2 toxcity of alopecia is observed 60%.

Conclusions

LV5FU2 with docetaxel combination chemotheraphy is effective and tolerable in patients with inoperable or postoperative relapsed gastric cancer.

Citations

Citations to this article as recorded by  
  • Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial
    Jian-Xian Lin, Yi-Hui Tang, Hua-Long Zheng, Kai Ye, Jian-Chun Cai, Li-Sheng Cai, Wei Lin, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Chao-Hui Zheng, Ping Li, Chang-Ming Huang
    Nature Communications.2024;[Epub]     CrossRef
  • Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
    P C Thuss-Patience, A Kretzschmar, Y Dogan, F Rothmann, I Blau, I Schwaner, K Breithaupt, D Bichev, M Grothoff, C Grieser, P Reichardt
    British Journal of Cancer.2011; 105(4): 505.     CrossRef
  • 8,999 View
  • 60 Download
  • 2 Crossref
Close layer
Prognostic Significance of Serum and Tissue Carcinoembryonic Antigen in Patients with Gastric Adenocarcinomas
Seong-Hoon Park, Ki-Beom Ku, Ho-Young Chung, Wansik Yu
Cancer Res Treat. 2008;40(1):16-21.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.16
AbstractAbstract PDFPubReaderePub
Purpose

Carcinoembryonic antigen (CEA) is known to be elevated in nearly all solid malignancies. The prognostic role of CEA in gastric cancers however, is still controversial. We evaluated preoperative serum CEA levels and CEA expression from the resected tumor tissues to determine whether they have prognostic significance in gastric cancer patients.

Materials and Methods

Medical records of 810 patients who underwent surgery for gastric adenocarcinoma from June, 1998 to February, 2002 in Kyungpook National University Hospital were reviewed. Serum CEA level was evaluated by radioimmunoassay preoperatively, and the cut-off level for positivity was 7.0 ng/ml. Labeled streptavidin-biotin peroxidase method was used to determine CEA expression from the gastric cancer tissues.

Results

Serum and tissue CEA were positive in 9.3% and 91.1% of the patients, respectively. They had no correlation with each other. The positivity rate of serum CEA had positive correlation with invasion depth (p<0.001), lymph node metastasis (p<0.001), distant metastasis (p=0.006), and final stage (p<0.001). Well differentiated tumors showed higher serum CEA positivity (p=0.002). Patients with positive serum CEA had higher recurrence rate (p<0.001). Multivariate analysis showed significantly lower survival rate in patients with preoperative CEA levels over 7 ng/ml than those with lower levels (48.0% vs. 80.7%; p<0.001). The positivity rates of tissue CEA were higher in advanced cancers (p=0.033) and in more advanced stages (p=0.029). Tissue CEA positivity showed no correlation with recurrence or survival.

Conclusions

Preoperative serum CEA level had correlation with disease progression and survival in gastric cancer patients, and proved to be an independent prognostic factor. Tissue CEA expression in gastric cancers had no prognostic information.

Citations

Citations to this article as recorded by  
  • In Pursuit of Novel Markers: Unraveling the Potential of miR-106, CEA and CA 19-9 in Gastric Adenocarcinoma Diagnosis and Staging
    Adrian Boicean, Ioana Boeras, Sabrina Birsan, Cristian Ichim, Samuel Bogdan Todor, Danusia Maria Onisor, Olga Brusnic, Ciprian Bacila, Horatiu Dura, Corina Roman-Filip, Maria Livia Ognean, Ciprian Tanasescu, Adrian Hasegan, Dan Bratu, Corina Porr, Iulian
    International Journal of Molecular Sciences.2024; 25(14): 7898.     CrossRef
  • Combined Use of Tumor Markers in Gastric Cancer: A Novel Method with Promising Prognostic Accuracy and Practicality
    Ruopeng Zhang, Xiaojiang Chen, Guoming Chen, Zhoukai Zhao, Yicheng Wei, Feiyang Zhang, Jun Lin, Runcong Nie, Yingbo Chen
    Annals of Surgical Oncology.2023; 30(13): 8561.     CrossRef
  • A novel hematological classifier predicting chemotherapy benefit and recurrence hazard for locally advanced gastric cancer A multicenter IPTW analysis
    Jun Lu, Dong Wu, Shi Chen, Jiao-bao Huang, Bin-bin Xu, Zhen Xue, Hua-Long Zheng, Guo-sheng Lin, Li-li Shen, Jia Lin, Chao-Hui Zheng, Ping Li, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Long-Long Cao, Jian-Wei Xie, Jun-sheng Peng, Chang-Ming Huang
    European Journal of Surgical Oncology.2022; 48(8): 1768.     CrossRef
  • Expression of Matrix Metalloproteinase-7 Predicts Poor Prognosis in Gastric Cancer
    Wareeporn Wattanawongdon, Theeraya Simawaranon Bartpho, Taweesak Tongtawee, Rosario Caltabiano
    BioMed Research International.2022; 2022: 1.     CrossRef
  • Clinical significance of tumor necrosis factor-alpha and carcinoembryonic antigen in gastric cancer
    Mihai Cătălin Roșu, Petrut Dinu Mihnea, Andrei Ardelean, Silviu Daniel Moldovan, Romana Olivia Popețiu, Bogdan Dan Totolici
    Journal of Medicine and Life.2022; 15(1): 4.     CrossRef
  • STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years
    Liyun Zhou, Zhenhua Jiang, Wenhui Gu, Shuangyin Han
    Medicine.2021; 100(26): e26336.     CrossRef
  • Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients
    Mahmood Rasool, Angel Carracedo, Abdulrahman Sibiany, Faten Al-Sayes, Sajjad Karim, Absarul Haque, Peter Natesan Pushparaj, Muhammad Asif, Niaz M. Achakzai
    Bioengineered.2021; 12(1): 5099.     CrossRef
  • Clinical significance of novel identified high‐frequency tumor‐specific peptides associated signature in predicting disease status of gastric cancer patients
    Bin Li, Huizhen Geng, Zibo Li, Bing Peng, Jinfeng Wang, Xiaolei Yin, Ning Li, Jianfei Shi, Man Zhao, Cuizhen Li, Fei Yin
    BioFactors.2021; 47(6): 1042.     CrossRef
  • Overexpression of CXCL8 gene in Saudi colon cancer patients
    Mahmood Rasool, Peter Natesan Pushparaj, Sajjad Karim
    Saudi Journal of Biological Sciences.2021; 28(11): 6045.     CrossRef
  • Fluorescent imaging for cancer therapy and cancer gene therapy
    Yanghee Woo, Shyambabu Chaurasiya, Michael O’Leary, Ernest Han, Yuman Fong
    Molecular Therapy - Oncolytics.2021; 23: 231.     CrossRef
  • The significance of preoperative serum carcinoembryonic antigen levels in the prediction of lymph node metastasis and prognosis in locally advanced gastric cancer: a retrospective analysis
    Keshen Wang, Xiangyan Jiang, Yanxian Ren, Zhijian Ma, Xiaocheng Cheng, Fan Li, Jingying Xiao, Zeyuan Yu, Zuoyi Jiao
    BMC Gastroenterology.2020;[Epub]     CrossRef
  • Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer
    Yasuhito Suenaga, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Chie Tanaka, Daisuke Kobayashi, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Koder
    World Journal of Gastrointestinal Oncology.2019; 11(1): 17.     CrossRef
  • Expression of serum tumor markers in gastric cancer with different degrees of differentiation: Significance for monitoring tumor recurrence
    Yong-Shun Gao, Yi-Ming Wang, Jing-Jing Huang, Yun-Fei Zhang, Peng Chen, Xi-Zhong Yan, Jian-Gang Sun, Xiao-Jin Fan, Ji Han, Zeng-Lang Chen
    World Chinese Journal of Digestology.2019; 27(6): 361.     CrossRef
  • Preoperative globulin‐to‐albumin ratio predicts outcome after curative resection in patients with gastric cancer
    Takayuki Shimizu, Mitsuru Ishizuka, Norisuke Shibuya, Genki Tanaka, Akihito Abe, Taku Aoki, Keiichi Kubota
    Annals of Gastroenterological Surgery.2018; 2(5): 367.     CrossRef
  • Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer
    Fan Feng, Yangzi Tian, Guanghui Xu, Zhen Liu, Shushang Liu, Gaozan Zheng, Man Guo, Xiao Lian, Daiming Fan, Hongwei Zhang
    BMC Cancer.2017;[Epub]     CrossRef
  • Blood type AB predicts promising prognosis in gastric cancer patients with positive preoperative serum CEA
    Shuao Xiao, Fan Feng, Li Sun, Lei Cai, Zhen Liu, Shushang Liu, Daiming Fan, Hongwei Zhang
    Medicine.2017; 96(47): e8496.     CrossRef
  • Prognostic significance of pretreatment serum carcinoembryonic antigen levels in gastric cancer with pathological lymph node-negative: A large sample single-center retrospective study
    Jun Xiao, Zai-Sheng Ye, Sheng-Hong Wei, Yi Zeng, Zhen-Meng Lin, Yi Wang, Wen-Hao Teng, Lu-Chuan Chen
    World Journal of Gastroenterology.2017; 23(48): 8562.     CrossRef
  • Prognostic Significance of Carcinoembryonic Antigen Staining in Cancer Tissues of Gastric Cancer Patients
    Wei Wang, Sharvesh Raj Seeruttun, Cheng Fang, Jiewei Chen, Yong Li, Zhimin Liu, Youqing Zhan, Wei Li, Yingbo Chen, Xiaowei Sun, Yuanfang Li, Dazhi Xu, Yuanxiang Guan, Zhiwei Zhou
    Annals of Surgical Oncology.2016; 23(4): 1244.     CrossRef
  • Prognostic values of normal preoperative serum cancer markers for gastric cancer
    Fan Feng, Li Sun, Zhen Liu, Shushang Liu, Gaozan Zheng, Guanghui Xu, Man Guo, Xiao Lian, Daiming Fan, Hongwei Zhang
    Oncotarget.2016; 7(36): 58459.     CrossRef
  • Preoperative Serum CEA and CA19-9 in Gastric Cancer - a Single Tertiary Hospital Study of 1,075 Cases
    Yang-Chun Zhou, Hai-Jian Zhao, Li-Zong Shen
    Asian Pacific Journal of Cancer Prevention.2015; 16(7): 2685.     CrossRef
  • Prognostic value of preoperative serum tumor markers in gastric cancer
    Ze-Bo Huang
    World Journal of Clinical Oncology.2014; 5(2): 170.     CrossRef
  • The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy
    Shi Chen, Xing‐Yu Feng, Yuan‐Fang Li, Bai‐Wei Zhao, Zhi‐Wei Zhou, Ying‐Bo Chen
    Journal of Surgical Oncology.2013; 107(6): 641.     CrossRef
  • Effect ofHelicobacter pyloriInfection on p16, p53, CEA, EGFR Expression in Gastric Neoplasia
    Chan Sik Won, Mee Yon Cho, Hyun Soo Kim, Ki Tae Suk, Jae Woo Kim, Hong Jun Park, Hyo Keun Jeon, Soon Koo Baik, Sang Ok Kwon
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2011; 11(1): 45.     CrossRef
  • Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
    Ji Soo Park, Jae Yun Lim, Seung Kyo Park, Min Kyung Kim, Hee Sung Ko, Sun Och Yoon, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
    Cancer Research and Treatment.2011; 43(4): 236.     CrossRef
  • A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis
    Hyung Soon Park, Sun Young Rha, Hyo Song Kim, Woo Jin Hyung, Ji Soo Park, Hyun Cheol Chung, Sung Hoon Noh, Hei-Cheul Jeung
    Oncology.2011; 80(1-2): 142.     CrossRef
  • 10,785 View
  • 82 Download
  • 25 Crossref
Close layer
Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis
Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim
Cancer Res Treat. 2008;40(1):22-26.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.22
AbstractAbstract PDFPubReaderePub
Purpose

Gemcitabine is the most active agent to treat unresectable pancreatic cancer. The superiority of combining other drugs with cisplatin is still controversial; therefore, we performed a retrospective analysis of gemcitabine versus gemcitabine combined with cisplatin to determine the treatment outcomes for patients with locally advanced or metastatic pancreatic cancer.

Materials and Methods

From 2001 to 2007, we enrolled 60 patients who were treated with gemcitabine or gemcitabine combined with cisplatin for locally advanced or metastatic pancreatic cancer. Gemcitabine 1, 000 mg/m2 (G) was administrated at day 1 and day 8 every 3 weeks. Cisplatin 60 mg/m2 was added at day 1 every 3 weeks to the gemcitabine schedule (GP).

Results

Number of G: GP was 34: 26, locally advanced to metastatic ratio was 35% to 65% in group G and 46% to 54% in group GP. Median follow up duration was 29 months. The median number of chemotherapy cycles was 4 (range: 2~11) for the G group, and 4 (range: 1~11) for the GP group. The response rate of the G and GP groups was 17% and 11%, respectively. The progression free survival (PFS) was 4.5 months and 2.8 months, respectively, for the G and GP groups. The overall survival (OS) was 10.7 and 8.7 months respectively, for the G and GP groups, but there is no statistically significant difference of the PFS (p=0.2396) and OS (p=0.4643) between the 2 groups. The hematological toxicity profile was similar (the grade III neutropenia and thrombocytopenia was 4.4% and 3.1%, respectively, in G group, and 7.5% and 2.8%, respectively, in the GP group). But non-hematological toxicities such as skin rash, abnormal liver function and nausea/vomiting were observed in 3 patients of the GP group. On the prognostic factor analysis, no factors predicted a longer PFS and OS for both the G and GP groups.

Conclusions

Gemcitabine single treatment might be more tolerable and it had the same efficacy compared to cisplatin combination treatment in this retrospective study.

Citations

Citations to this article as recorded by  
  • Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
    David J. Kuter
    Haematologica.2022; 107(6): 1243.     CrossRef
  • Treatment of drug-induced immune thrombocytopenias
    Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul
    Haematologica.2022; 107(6): 1264.     CrossRef
  • Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer
    Giuseppe Belfiore, Maria Paola Belfiore, Alfonso Reginelli, Raffaella Capasso, Francesco Romano, Giovanni Pietro Ianniello, Salvatore Cappabianca, Luca Brunese
    Medical Oncology.2017;[Epub]     CrossRef
  • Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
    Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Paul Burgess, Stacey Kalambakas, Yasser Mostafa Kamel, Frederic Forget
    International Journal of Hematology.2017; 106(6): 765.     CrossRef
  • Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study
    Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan M. Johnson, Conrad A. Messam, Yasser Mostafa Kamel
    Cancer Medicine.2015; 4(1): 16.     CrossRef
  • Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer
    Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao
    Clinical Therapeutics.2014; 36(7): 1054.     CrossRef
  • Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
    Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
    PLoS ONE.2014; 9(8): e104346.     CrossRef
  • Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines
    Samantha B. Kasloff, Matteo S. Pizzuto, Micol Silic-Benussi, Silvia Pavone, Vincenzo Ciminale, Ilaria Capua, K. L. Beemon
    Journal of Virology.2014; 88(16): 9321.     CrossRef
  • Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer
    Wenbo Zhu, Jingjie Li, Sihan Wu, Shifeng Li, Liang Le, Xingwen Su, Pengxin Qiu, Haiyan Hu, Guangmei Yan
    Pancreas.2012; 41(7): 1029.     CrossRef
  • 11,260 View
  • 57 Download
  • 9 Crossref
Close layer
Effect on Cell Cycle Progression by N-Myc Knockdown in SK-N-BE(2) Neuroblastoma Cell Line and Cytotoxicity with STI-571 Compound
Un-Young Yu, Je-Eun Cha, Sun-Young Ju, Kyung-Ah Cho, Eun-Sun Yoo, Kyung-Ha Ryu, So-Youn Woo
Cancer Res Treat. 2008;40(1):27-32.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.27
AbstractAbstract PDFPubReaderePub
Purpose

Neuroblastoma is a common tumor in childhood, and generally exhibits heterogeneity and a malignant progression. MYCN expression and amplification profiles frequently correlate with therapeutic prognosis. Although it has been reported that MYCN silencing causes differentiation and apoptosis in human neuroblastoma cells, MYCN expression influences the cytotoxic potential of chemotherapeutic drugs via the deregulation of the cell cycle. STI-571 may constitute a promising therapeutic agent against neuroblastoma, particularly in cases in which c-Kit is expressed preferentially in MYCN-amplified neuroblastoma.

Materials and Methods

To determine whether STI-571 exerts a synergistic effect on cytotoxicity with MYCN expression, we assessed apoptotic cell death and cell cycle distribution after 72 h of exposure to STI-571 with or with out treatment of SK-N-BE(2) neuroblastoma cells with MYCN siRNA.

Results

MYCN siRNA-treated SK-N-BE(2) cells did not affect apoptosis and cells were arrested in G0/G1 phase after STI-571 treatment.

Conclusions

siRNA therapy targeted to MYCN may not be effective when administered in combination with STI-571 treatment in cases of neuroblastoma. Therefore, chemotherapeutic drugs that target S or G2-M phase may prove ineffective when applied to cells arrested in the G0/1 phase as the result of MYCN knockdown and STI-571 treatment.

Citations

Citations to this article as recorded by  
  • Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling
    Timofey Lebedev, Anton Buzdin, Elmira Khabusheva, Pavel Spirin, Maria Suntsova, Maxim Sorokin, Vladimir Popenko, Petr Rubtsov, Vladimir Prassolov
    International Journal of Molecular Sciences.2022; 23(14): 7724.     CrossRef
  • The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells
    Long Gu, Peiguo Chu, Robert Lingeman, Heather McDaniel, Steven Kechichian, Robert J. Hickey, Zheng Liu, Yate-Ching Yuan, John A. Sandoval, Gregg B. Fields, Linda H. Malkas
    EBioMedicine.2015; 2(12): 1923.     CrossRef
  • Comparative analysis of gene expression: Targeted antitumor therapy in neuroblastoma cell lines
    T. D. Lebedev, P. V. Spirin, N. N. Orlova, M. M. Prokofjeva, V. S. Prassolov
    Molecular Biology.2015; 49(6): 939.     CrossRef
  • A PCNA-Derived Cell Permeable Peptide Selectively Inhibits Neuroblastoma Cell Growth
    Long Gu, Shanna Smith, Caroline Li, Robert J. Hickey, Jeremy M. Stark, Gregg B. Fields, Walter H. Lang, John A. Sandoval, Linda H. Malkas, Anja-Katrin Bielinsky
    PLoS ONE.2014; 9(4): e94773.     CrossRef
  • SUMOylation of Myc-Family Proteins
    Arianna Sabò, Mirko Doni, Bruno Amati, Ramin Massoumi
    PLoS ONE.2014; 9(3): e91072.     CrossRef
  • Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
    Jørn R Henriksen, Bjørn Helge Haug, Jochen Buechner, Ellen Tømte, Cecilie Løkke, Trond Flaegstad, Christer Einvik
    BMC Developmental Biology.2011;[Epub]     CrossRef
  • 9,374 View
  • 67 Download
  • 6 Crossref
Close layer
Case Reports
Intestinal Perforation in Colorectal Cancers Treated with Bevacizumab (Avastin®)
Young Il Choi, Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek, Seun Ja Park, Yang Soo Kim, Seong Hoon Shin
Cancer Res Treat. 2008;40(1):33-35.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.33
AbstractAbstract PDFPubReaderePub

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab use, but the etiology is unknown. Here we report on two cases of metastatic colorectal cancer in which the patients suffered from intestinal perforation after chemotherapy with bevacizumab. For the first case, a 47 year-old man had rectal cancer with concurrent liver and lung metastasis. He underwent chmotherapy with 5-fluorouracil, irinotecan and bevacizumab. Fever and abdominal pain developed seven days later, and rectal perforation was identified upon exploration 13 days later. For the second case, a 48 year-old woman had sigmoid colon cancer with peritoneal and ovary metastases. After seven days of chemotherapy with 5-fluorouracil, oxaliplatin and bevacizumab, exploratory surgery revealed a perforation at the ileum.

Citations

Citations to this article as recorded by  
  • Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
    Jai N. Patel, Chen Jiang, Kouros Owzar, Daniel L. Hertz, Janey Wang, Flora A. Mulkey, William K. Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G. Dorsey, Paula N. Friedman, Eric J. Small, Michael A. Carducci, Michael J. Kelley, Yusuke Naka
    The Pharmacogenomics Journal.2024;[Epub]     CrossRef
  • Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
    Akihiko Ueda, Hidemichi Watari, Masaki Mandai, Shunichi Fukuhara, Yasuo Sugitani, Kiyoko Ogino, Shuichi Kamijima, Takayuki Enomoto
    Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
  • Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement
    Pratima Dibba, Emmy Ludwig, Delia Calo, Hans Gerdes, Arnold Markowitz, Moshe Shike, Mark Schattner, Robin Mendelsohn
    Surgical Endoscopy.2021; 35(6): 2976.     CrossRef
  • Evolution of pediatric gastrointestinal ulcer disease: Is acute surgical intervention relevant?
    Alyssa D. Brown, Michael D. Traynor, D. Dean Potter, Michael B. Ishitani, Christopher R. Moir, Paul J. Galardy, Denise B. Klinkner
    Journal of Pediatric Surgery.2021; 56(10): 1870.     CrossRef
  • A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed
    Shuncong Wang, Yewei Liu, Yuanbo Feng, Jian Zhang, Johan Swinnen, Yue Li, Yicheng Ni
    Cancers.2019; 11(11): 1782.     CrossRef
  • Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer
    Motohiro Tamiya, Hidekazu Suzuki, Takayuki Shiroyama, Ayako Tanaka, Naoko Morishita, Norio Okamoto, Kenichi Sakai, Hironori Shigeoka, Kunimitsu Kawahara, Tomonori Hirashima
    Investigational New Drugs.2018; 36(4): 696.     CrossRef
  • A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
    Shinya Urakawa, Daisuke Sakai, Yasuhiro Miyazaki, Toshihiro Kudo, Aya Katou, Chiaki Inagaki, Koji Tanaka, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Taroh Satoh, Masaki Mori, Yuichiro Doki
    Surgical Case Reports.2017;[Epub]     CrossRef
  • Sigmoid Colon Perforation Related to Bevacizumab in a Patient With Glioblastoma
    Mehmet Akif Ozturk, Baran Erdik, Orhan Onder Eren
    American Journal of Therapeutics.2016; 23(1): e241.     CrossRef
  • When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab
    Jeffrey Chen, Roger D. Smalligan, Suhasini Nadesan
    Hospital Practice.2016; 44(3): 120.     CrossRef
  • Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials
    Zexing Wang, Jun Zhang, Liang Zhang, Pengying Liu, Yamin Xie, Qin Zhou
    Journal of Chemotherapy.2016; 28(4): 328.     CrossRef
  • Safety and Efficacy of Palliative Colorectal Stent Placement Using a Nasal Endoscope Technique
    Taishi Hata, Shiro Hayashi, Masakazu Miyake, Shunji Morita, Keizo Dono
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2015; 25(3): 262.     CrossRef
  • Multidetector-row CT of tumour–bowel fistula: Experience at a tertiary cancer centre
    S.H. Tirumani, A.B. Shinagare, J.P. Jagannathan, K.M. Krajewski, N.H. Ramaiya
    Clinical Radiology.2014; 69(2): e100.     CrossRef
  • Bowel perforation associated with temsirolimus use in a recently irradiated patient
    Claire M. Mach, Anze Urh, Matthew L. Anderson
    American Journal of Health-System Pharmacy.2014; 71(11): 919.     CrossRef
  • Complications of Targeted Drug Therapies for Solid Malignancies: Manifestations and Mechanisms
    Richard G. Abramson, Vandana G. Abramson, Emily Chan, Leora Horn, Vicki L. Keedy, William Pao, Jeffrey A. Sosman
    American Journal of Roentgenology.2013; 200(3): 475.     CrossRef
  • Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period
    S S Wickremasinghe, J Xie, R H Guymer, T Y Wong, R Kawasaki, S Qureshi
    Eye.2012; 26(7): 958.     CrossRef
  • Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model
    Guillaume Passot, Aurélien Dupré, Michel Rivoire, Faheez Mohamed, Naoual Bakrin, Olivier Glehen
    Clinical and Translational Oncology.2012; 14(12): 931.     CrossRef
  • Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study
    Terence C. Chua, David L. Morris, Akshat Saxena, Jesus Esquivel, Winston Liauw, Joerg Doerfer, Christoph-Thomas Germer, Alexander G. Kerscher, Joerg O. W. Pelz
    Annals of Surgical Oncology.2011; 18(6): 1560.     CrossRef
  • A Case of Severe Bevacizumab-induced Ischemic Pancolitis, Treated with Conservative Management
    Ha Ni Lee, Myung-Ah Lee, Sang Woo Kim, Yejee Lim, Hwayoung Lee, Hae Min Lee, Hye Sung Won, Sang-Hoon Chun
    The Korean Journal of Gastroenterology.2011; 58(1): 42.     CrossRef
  • Perforated Rectal Cancer Presenting as Fournier's Gangrene
    John Alfred Carr
    Journal of Clinical Oncology.2010; 28(30): e605.     CrossRef
  • 12,334 View
  • 93 Download
  • 19 Crossref
Close layer
Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy
Eui Bae Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Kyoung Ho Rho, Seok Jin Kim
Cancer Res Treat. 2008;40(1):36-38.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.36
AbstractAbstract PDFPubReaderePub

Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.

Citations

Citations to this article as recorded by  
  • Very late-onset hepatitis B reactivation following chemoimmunotherapy
    Edward R. Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg
    Leukemia & Lymphoma.2022; 63(4): 991.     CrossRef
  • Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients
    Jieni Yu, Zhiqiang Xu, Yuanyuan Zhuo, Huahua Wei, Yinhai Ye, Qinhong Xu, Youli Li, Lihong Yu, Weiying Feng, Pan Hong, Kejie Zhang
    Hematology.2021; 26(1): 956.     CrossRef
  • Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency
    Masako Hatano, Toshihide Mimura, Akira Shimada, Mitsuhiko Noda, Shigehiro Katayama
    Endocrinology, Diabetes & Metabolism.2019;[Epub]     CrossRef
  • Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen
    Nuria Dominguez, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano
    Leukemia & Lymphoma.2015; 56(4): 1160.     CrossRef
  • Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
    Jesse Civan, Hie Won Hann
    Expert Opinion on Drug Safety.2015; 14(6): 865.     CrossRef
  • Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy
    Mauro Viganò, Giampaolo Mangia, Pietro Lampertico
    Expert Opinion on Biological Therapy.2014; 14(7): 1019.     CrossRef
  • A Case of Reactivation of Hepatitis B and Fulminant Hepatitis which developed 3 months following Chemotherapy Including Rituximab in a Patient with Lymphoma
    Tae Won Lim, Hee Taek Oh, Seung Un Song, Hae Won Lee, Ji Yeon Kim, Seon Ja Park
    Kosin Medical Journal.2014; 29(2): 161.     CrossRef
  • Occult Hepatitis B Virus Infection: Transmission and Reactivation
    Sang Hee Song, Seong Gyu Hwang
    The Korean Journal of Gastroenterology.2013; 62(3): 148.     CrossRef
  • Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma
    Seung Jun Jang, Young Kul Jung, Hae Lim Baek, Hyun Hwa Yoon, Seung Kak Shin, Jun Shik Hong, Jin Ny Park, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Jae Hoon Lee, Ju Hyun Kim
    Korean Journal of Medicine.2013; 85(6): 598.     CrossRef
  • Occult Hepatitis B: Clinical Viewpoint and Management
    Mehdi Zobeiri
    Hepatitis Research and Treatment.2013; 2013: 1.     CrossRef
  • Highly Sensitive Detection of Hepatitis B Virus Surface Antigen by Use of a Semiautomated Immune Complex Transfer Chemiluminescence Enzyme Immunoassay
    Kazuhiko Takeda, Mari Maruki, Takahiro Yamagaito, Machiko Muramatsu, Yasuhiro Sakai, Hiroaki Tobimatsu, Hironori Kobayashi, Yoshiteru Mizuno, Yukio Hamaguchi
    Journal of Clinical Microbiology.2013; 51(7): 2238.     CrossRef
  • Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
    Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami
    Journal of Gastroenterology.2011; 46(1): 9.     CrossRef
  • Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
    Seong Min Chung, Joo Hyun Sohn, Tae Yeob Kim, Ki Deok Yoo, Yong Woo Ahn, Joong Ho Bae, Yong Cheol Jeon, Jung Hye Choi
    The Korean Journal of Gastroenterology.2010; 55(4): 266.     CrossRef
  • Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
    Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Angela Granata, Arianna D’Angelo, Caterina Musolino
    Medical Oncology.2010; 27(3): 912.     CrossRef
  • 14,201 View
  • 91 Download
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP